Icon PLC CEO Steve Cutler to Retire; Barry Balfe to Take Over on Oct. 1
ByAinvest
Thursday, Sep 4, 2025 8:59 am ET1min read
ICLR--
Mr. Balfe, who has been with ICON for over two decades, has been the Chief Operating Officer since January 2025. Prior to his appointment as COO, he served as President of Functional Services and then as President of Pharma Solutions. ICON’s Chair, Mr. Ciaran Murray, praised Mr. Balfe’s record of success in leadership roles within the company and noted that his appointment follows a comprehensive succession planning process.
Dr. Cutler, who has been with ICON for 14 years, thanked the board, executive team, employees, and customers for their support during his tenure. He expressed confidence in Mr. Balfe’s ability to lead ICON to further growth and success. Mr. Balfe, in turn, expressed his honor and excitement at the opportunity to lead ICON during a pivotal time in the industry, with a focus on accelerating the development of novel therapeutics and enhancing customer value through increased efficiency and innovation.
ICON plc employs approximately 39,900 people in 95 locations across 55 countries, as of June 30, 2025. The company is known for its healthcare intelligence and provides outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations.
The press release includes forward-looking statements, which are subject to future events, risks, and uncertainties. These statements are based on current expectations and information available as of the date of the press release.
References:
[1] https://www.iconplc.com/news-events/press-releases/icon-announces-ceo-transition
[2] https://www.stocktitan.net/news/ICLR/icon-announces-ceo-8216goevjdy2.html
Icon PLC CEO Steve Cutler is retiring, with Barry Balfe, currently COO, set to succeed him on October 1. Cutler will continue as a non-executive director to assist with the transition. Balfe has spent over two decades with Icon and has been COO since December. He will join the board.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, has announced the retirement of its CEO, Dr. Steve Cutler, and the appointment of Mr. Barry Balfe as his successor. The transition will take place on October 1, 2025, with Mr. Balfe assuming the role of CEO and joining the board. Dr. Cutler will continue to serve as a non-executive director to facilitate a smooth transition.Mr. Balfe, who has been with ICON for over two decades, has been the Chief Operating Officer since January 2025. Prior to his appointment as COO, he served as President of Functional Services and then as President of Pharma Solutions. ICON’s Chair, Mr. Ciaran Murray, praised Mr. Balfe’s record of success in leadership roles within the company and noted that his appointment follows a comprehensive succession planning process.
Dr. Cutler, who has been with ICON for 14 years, thanked the board, executive team, employees, and customers for their support during his tenure. He expressed confidence in Mr. Balfe’s ability to lead ICON to further growth and success. Mr. Balfe, in turn, expressed his honor and excitement at the opportunity to lead ICON during a pivotal time in the industry, with a focus on accelerating the development of novel therapeutics and enhancing customer value through increased efficiency and innovation.
ICON plc employs approximately 39,900 people in 95 locations across 55 countries, as of June 30, 2025. The company is known for its healthcare intelligence and provides outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations.
The press release includes forward-looking statements, which are subject to future events, risks, and uncertainties. These statements are based on current expectations and information available as of the date of the press release.
References:
[1] https://www.iconplc.com/news-events/press-releases/icon-announces-ceo-transition
[2] https://www.stocktitan.net/news/ICLR/icon-announces-ceo-8216goevjdy2.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet